High initial drug doses may reduce cancer drug resistance

Editorial Checklist Reviewed
Aging-USAug 6 2024NewsGuard 100/100 Score

On July 28, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new editorial in Volume 16, Issue 14 of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), entitled, "Targeted cancer therapy: the initial high concentration may slow down the selection for resistance."

"Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance. One should propose that initial drug levels must be maximized, and durations may be minimized, ideally, as portions of preemptive combination of targeted drugs."

Source:

Aging-US

Journal reference:

Blagosklonny, M. V. (2024). Targeted cancer therapy: the initial high concentration may slow down the selection for resistance. Aging. doi.org/10.18632/aging.206046.

Posted in: Medical Research News | Medical Condition News

Tags: , , , , , , , , , ,

Comments (0)

Suggested Reading

Surprising discovery in yeast could open the door to new cancer treatments
New grant aims to transform treatment for liver cancer
Immunotherapy yields complete response in stage IV lung cancer
Scientists map the genetic landscape of drug resistance in cancers
Breakthrough discovery of selective MMP7 inhibitor offers hope for cancer treatment
Higher diet quality associated with reduced risk of prostate cancer grade reclassification
Studies reveal unique challenges faced by younger patients with colorectal cancer
Study links healthy diet to reduced progression of low-risk prostate cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer